Evidence map›Paper›PMID 34874004›Full record

ArticleeLife2021

Characterization of the endogenous DAF-12 ligand and its use as an anthelmintic agent in

Zhu Wang, Mi Cheong Cheong, Jet Tsien, Heping Deng, Tian Qin, Jonathan Dc Stoltzfus, Tegegn G Jaleta, Xinshe Li, James B Lok, Steven A Kliewer and 1 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Invade or die: behaviours and biochemical mechanisms that drive skin penetration inPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024
    Review
  8. Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024
    Review
  9. Article
  10. Molecular Cloning and Characterization of aPathogens (Basel, Switzerland) · 2022
    Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Zhu WangDepartment of Pharmacology, University of Texas Southwestern Medical Center, Dallas, United States.ORCID https://orcid.org/0000-0003-0768-0988
Mi Cheong CheongDepartment of Pharmacology, University of Texas Southwestern Medical Center, Dallas, United States.
Jet TsienDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, United States.ORCID https://orcid.org/0000-0002-2052-8051
Heping DengDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, United States.
Tian QinDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, United States.
Jonathan Dc StoltzfusDepartment of Biology, Millersville University of Pennsylvania, Millersville, United States.ORCID https://orcid.org/0000-0002-4006-5306
Tegegn G JaletaDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, United States.
Xinshe LiDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, United States.
James B LokDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, United States.
Steven A KliewerDepartment of Pharmacology, University of Texas Southwestern Medical Center, Dallas, United States.ORCID https://orcid.org/0000-0001-5161-641X
David J MangelsdorfDepartment of Pharmacology, University of Texas Southwestern Medical Center, Dallas, United States.ORCID https://orcid.org/0000-0002-4355-0796
The University of Texas Southwestern Medical Center · USUniversity of Pennsylvania · USHoward Hughes Medical Institute · USMillersville University · US

Funding

Development of Sulfur-Based Reactions with Translational ApplicationsR01GM141088 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI Tian Qin · 2021 to 2026
$2.1M
Mechanisms and Treatment of Chronic, Latent Human StrongyloidiasisR33AI105856 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ABRAHAM, DAVID, LOK, JAMES B · 2015 to 2017
$1.4M
Mechanisms and Treatment of Chronic, Latent Human StrongyloidiasisR21AI105856 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ABRAHAM, DAVID, LOK, JAMES B · 2013 to 2014
$444k
Howard Hughes Medical InstituteNIAID NIH HHS R21 AI105856NIAID NIH HHS R33 AI105856NIGMS NIH HHS R01 GM141088
6 · The paper itself

Abstract

A prevalent feature of

Indexed as

AnimalsAnthelminticsCaenorhabditis elegansCaenorhabditis elegans ProteinsDogsGerbillinaeIvermectinLigandsMaleReceptors, Cytoplasmic and NuclearStrongyloides stercoralisStrongyloidiasisAnthelminticsCaenorhabditis elegans ProteinsIvermectinLigandsReceptors, Cytoplasmic and Nuclearcytochrome P450DAF-12gerbilinfectious diseaseivermectinmicrobiologynematode parasitismnuclear receptorStrongyloides stercoralis

Identifiers

PMID34874004
PMCPMC8651287
OpenAlexW4226178502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.